LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer's DiseaseGlobeNewsWire • Thursday
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response MeasureGlobeNewsWire • Monday
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View TightenedZacks Investment Research • 10/28/26
Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 10/28/26
Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its ReportInvestors Business Daily • 10/28/26
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?Zacks Investment Research • 10/23/26
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The NormSeeking Alpha • 10/21/26
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/21/26
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowZacks Investment Research • 10/20/26
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney WeekGlobeNewsWire • 10/19/26
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies saysProactive Investors • 10/06/26
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/06/26